SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-13-433952
Filing Date
2013-11-08
Accepted
2013-11-08 06:57:56
Documents
10
Period of Report
2013-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d591280d10q.htm 10-Q 599910
2 EX-31.1 d591280dex311.htm EX-31.1 9529
3 EX-31.2 d591280dex312.htm EX-31.2 9340
4 EX-32.1 d591280dex321.htm EX-32.1 5506
  Complete submission text file 0001193125-13-433952.txt   4598269

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT vnda-20130930.xml EX-101.INS 479037
6 XBRL TAXONOMY EXTENSION SCHEMA vnda-20130930.xsd EX-101.SCH 58849
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vnda-20130930_cal.xml EX-101.CAL 70512
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnda-20130930_def.xml EX-101.DEF 310447
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20130930_lab.xml EX-101.LAB 395730
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20130930_pre.xml EX-101.PRE 377959
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 131202490
SIC: 2834 Pharmaceutical Preparations